United States - Map
Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor and cell filtration products, which are used to increase cell growth and productivity during the fermentation step of biomanufacturing, and chromatography products for purification of biologic products. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality control test kits. Further, it has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreichs ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yield during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
|Repligen Corporation’s ISS Governance QuickScore as of Mar 1, 2015 is 2. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 2; Compensation: 4.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Walter C. Herlihy Ph.D.,
Chief Exec. Officer, Pres, Director and Chairman of Science & Technology Committee
|Mr. Howard Benjamin Ph.D.,
VP of Bus. Devel.
|Dr. James R. Rusche Ph.D.,
Sr. VP of R&D
|Dr. Daniel P. Witt Ph.D.,
|Mr. Jon K. Snodgres ,
Chief Financial Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|